Signals, Powered By EquityPandit
Cipla has received green signal for Isoproterenol Hydrochloride injection, from the US health regulator. It is used for treating cardiac problems, in the American market.
The company stated that, it has received final approval from the United States Food and Drug Administration (USFDA) for its product which is a generic version of Hospira Inc’s Isuprel injection. Further, the product is suggested for serious episodes of heart block and cardiac arrest, until electric shock or pacemaker therapy is available.
